RecruitingPhase 1Phase 2NCT04982796
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Sponsor
Portland VA Research Foundation, Inc
Enrollment
30 participants
Start Date
Jul 7, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
Eligibility
Min Age: 25 YearsMax Age: 65 Years
Inclusion Criteria3
- United States military Veteran
- Moderate to severe methamphetamine use disorder using the DSM-V diagnostic criteria
- Desire to cease or reduce methamphetamine use
Exclusion Criteria10
- Have uncontrolled hypertension or clinically significant cardiovascular disease
- History of seizure disorder in adulthood
- CNS metastases or symptomatic central nervous system (CNS) infection
- Poorly controlled diabetes mellitus
- Taking certain medications that may interact with psilocybin
- History of any primary persistent psychotic disorder, including schizophrenia, schizoaffective disorder, bipolar disorder with psychosis, major depressive disorder with psychosis, or schizophreniform disorder
- History of bipolar I disorder
- Current eating disorder with active purging
- History of hallucinogen use disorder
- Pregnant or breast feeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPsilocybin
See description of psilocybin-enhanced psychotherapy arm.
BEHAVIORALTreatment-as-usual
See description of treatment-as-usual arm.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04982796